Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,044.66 -12.36 (-1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 364,286
Open 1,054.00
Bid (Size) 1,024.75 (1)
Ask (Size) 1,045.02 (1)
Prev. Close 1,057.02
Today's Range 1,030.23 - 1,058.17
52wk Range 688.52 - 1,081.17
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval of odronextamab. Final decision... 
Via Benzinga

Performance

YTD
+15.43%
+15.43%
1 Month
+5.58%
+5.58%
3 Month
+9.43%
+9.43%
6 Month
+15.43%
+15.43%
1 Year
+45.48%
+45.48%

More News

Read More
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
Via Benzinga
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
Via Benzinga
Exposures Product Safety
3 Biotech Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Via Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Via Benzinga
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Via Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Via Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
Via The Motley Fool
What's Going On With FibroGen Stock Tuesday?
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.